Medpro acquisition likely to be EPS accretive: Cipla
Cipla management is confident that the upside from Medpro acquisition is likely to be Earnings Per Share (EPS) accretive, though only from the second year onwards. Africa offers a market opportunity of close to $45 billion and is the next key market for Cipla among global space.
